CA2865845C - An iloperidone metabolite for use in the treatment of psychiatric disorders - Google Patents
An iloperidone metabolite for use in the treatment of psychiatric disorders Download PDFInfo
- Publication number
- CA2865845C CA2865845C CA2865845A CA2865845A CA2865845C CA 2865845 C CA2865845 C CA 2865845C CA 2865845 A CA2865845 A CA 2865845A CA 2865845 A CA2865845 A CA 2865845A CA 2865845 C CA2865845 C CA 2865845C
- Authority
- CA
- Canada
- Prior art keywords
- day
- iloperidone
- once daily
- disorder
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261610664P | 2012-03-14 | 2012-03-14 | |
| US61/610,664 | 2012-03-14 | ||
| PCT/US2013/031413 WO2013138602A1 (en) | 2012-03-14 | 2013-03-14 | An iloperidone metabolite for use in the treatment of psychiatric disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2865845A1 CA2865845A1 (en) | 2013-09-19 |
| CA2865845C true CA2865845C (en) | 2020-02-18 |
Family
ID=48407766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2865845A Active CA2865845C (en) | 2012-03-14 | 2013-03-14 | An iloperidone metabolite for use in the treatment of psychiatric disorders |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10874659B2 (enExample) |
| EP (2) | EP3345603B1 (enExample) |
| JP (5) | JP2015510893A (enExample) |
| KR (2) | KR20170008327A (enExample) |
| CN (2) | CN108938632A (enExample) |
| AU (2) | AU2013232014B2 (enExample) |
| BR (1) | BR112014022687A8 (enExample) |
| CA (1) | CA2865845C (enExample) |
| CL (1) | CL2014002430A1 (enExample) |
| CO (1) | CO7091183A2 (enExample) |
| ES (2) | ES2773711T3 (enExample) |
| IL (1) | IL234412B (enExample) |
| IN (1) | IN2014DN08495A (enExample) |
| MX (1) | MX374067B (enExample) |
| RU (1) | RU2651710C2 (enExample) |
| WO (1) | WO2013138602A1 (enExample) |
| ZA (1) | ZA201406369B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2870498T3 (es) | 2015-02-17 | 2021-10-27 | Vanda Pharmaceuticals Inc | Iloperidona para el tratamiento de esquizofrenia |
| US11214827B2 (en) * | 2018-08-30 | 2022-01-04 | Vanda Pharmaceuticals Inc. | Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone |
| JP2026504721A (ja) | 2022-12-19 | 2026-02-09 | バンダ・ファーマシューティカルズ・インコーポレイテッド | 双極ｉ型障害及び統合失調症の治療のためのイロペリドンの投与レジメン |
| WO2024249952A1 (en) * | 2023-06-02 | 2024-12-05 | Vanda Pharmaceuticals Inc. | Method of treatment with iloperidone |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5364866A (en) | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
| US7029694B2 (en) | 2000-04-26 | 2006-04-18 | Watson Laboratories, Inc. | Compositions and methods for transdermal oxybutynin therapy |
| DK2305656T3 (da) | 2001-08-31 | 2013-02-11 | Novartis Ag | Optiske isomerer of en iloperidonmetabolit |
| PT1458888E (pt) | 2001-12-10 | 2011-06-01 | Novartis Ag | Métodos para tratar a psicose e a esquizofrenia baseados em polimorfismos no gene do cntf |
| TW200410955A (en) | 2002-07-29 | 2004-07-01 | Altana Pharma Ag | Novel salt of (S)-PANTOPRAZOLE |
| GB0322994D0 (en) * | 2003-10-01 | 2003-11-05 | Novartis Ag | Organic compounds |
| CA3113166A1 (en) | 2004-09-30 | 2006-04-13 | Vanda Pharmaceuticals Inc. | Methods for the administration of iloperidone |
| US20100063093A1 (en) * | 2007-03-28 | 2010-03-11 | Curt Wolfgang | Methods for the administration of iloperidone |
| AU2007253684A1 (en) * | 2006-05-22 | 2007-11-29 | Vanda Pharmaceuticals, Inc. | Treatment for depressive disorders |
| EP2134873B1 (en) | 2007-03-29 | 2015-05-06 | Vanda Pharmaceuticals Inc. | Method of predicting a predisposition to qt prolongation |
| EP2198048A2 (en) | 2007-09-10 | 2010-06-23 | Vanda Pharmaceuticals Inc. | Prediction of qt prolongation based on snp genotype |
| WO2009036056A1 (en) | 2007-09-10 | 2009-03-19 | Vanda Pharmaceuticals, Inc. | Antipsychotic treatment based on snp genotype |
| CA2757723C (en) | 2009-04-06 | 2018-07-24 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to qt prolongation based on abcc2 gene sequence or product thereof |
| HUE037724T2 (hu) | 2009-04-06 | 2018-09-28 | Vanda Pharmaceuticals Inc | Eljárás a KCNQ1 gén polimorfizmusán alapuló kezelésre |
| EP2417266B1 (en) | 2009-04-06 | 2016-03-09 | Vanda Pharmaceuticals Inc. | Method of predicting a predisposition to qt prolongation |
| US9072742B2 (en) | 2009-04-06 | 2015-07-07 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to QT prolongation |
| CA2760474C (en) | 2009-05-15 | 2020-08-18 | Vanda Pharmaceuticals Inc. | Antipsychotic treatment based on drd2 or ankk1 snp genotype |
-
2013
- 2013-03-14 IN IN8495DEN2014 patent/IN2014DN08495A/en unknown
- 2013-03-14 JP JP2015500615A patent/JP2015510893A/ja active Pending
- 2013-03-14 CA CA2865845A patent/CA2865845C/en active Active
- 2013-03-14 KR KR1020177001093A patent/KR20170008327A/ko not_active Ceased
- 2013-03-14 US US14/384,401 patent/US10874659B2/en active Active
- 2013-03-14 EP EP18152636.9A patent/EP3345603B1/en active Active
- 2013-03-14 RU RU2014141112A patent/RU2651710C2/ru active
- 2013-03-14 BR BR112014022687A patent/BR112014022687A8/pt not_active Application Discontinuation
- 2013-03-14 AU AU2013232014A patent/AU2013232014B2/en active Active
- 2013-03-14 ES ES18152636T patent/ES2773711T3/es active Active
- 2013-03-14 EP EP13721817.8A patent/EP2825167B1/en active Active
- 2013-03-14 ES ES13721817.8T patent/ES2677474T3/es active Active
- 2013-03-14 CN CN201810683727.2A patent/CN108938632A/zh active Pending
- 2013-03-14 CN CN201380013841.XA patent/CN104203240A/zh active Pending
- 2013-03-14 KR KR1020147026434A patent/KR20140121487A/ko not_active Ceased
- 2013-03-14 WO PCT/US2013/031413 patent/WO2013138602A1/en not_active Ceased
- 2013-03-14 MX MX2014010989A patent/MX374067B/es active IP Right Grant
-
2014
- 2014-08-29 ZA ZA2014/06369A patent/ZA201406369B/en unknown
- 2014-09-01 IL IL234412A patent/IL234412B/en active IP Right Grant
- 2014-09-12 CL CL2014002430A patent/CL2014002430A1/es unknown
- 2014-10-09 CO CO14224666A patent/CO7091183A2/es unknown
-
2016
- 2016-05-30 AU AU2016203591A patent/AU2016203591B2/en active Active
- 2016-11-07 JP JP2016217680A patent/JP2017061506A/ja active Pending
-
2018
- 2018-09-10 JP JP2018169090A patent/JP7151029B2/ja active Active
-
2020
- 2020-09-28 JP JP2020162569A patent/JP2021001221A/ja active Pending
- 2020-09-30 US US17/039,769 patent/US20210015809A1/en not_active Abandoned
-
2022
- 2022-12-01 JP JP2022192922A patent/JP2023022243A/ja active Pending
-
2023
- 2023-09-26 US US18/373,205 patent/US20240016791A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240016791A1 (en) | Iloperidone metabolite for use in the treatment of psychiatric disorders | |
| US20090068290A1 (en) | Bifeprunox doses for treating schizophrenia | |
| US20090023712A1 (en) | Pharmaceutical Compositions for the Treatment of Attention Deficit Hyperactivity Disorder Comprising Flibanserin | |
| WO2006096435A1 (en) | Pharmaceutical compositions for the treatment and/or prevention of depression | |
| KR20250069704A (ko) | 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법 | |
| WO2008025781A1 (en) | Bifeprunox doses for treating schizophrenia | |
| JP7208139B2 (ja) | 双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用 | |
| HK1250490B (en) | Iloperidone metabolite for use in the treatment of psychiatric disorders | |
| HK1250490A1 (en) | Iloperidone metabolite for use in the treatment of psychiatric disorders | |
| JP5559696B2 (ja) | 糖尿病性腎症の治療剤 | |
| JP2025087929A (ja) | うつ病および／またはうつ状態の治療および／または予防用医薬 | |
| CN101573117A (zh) | 用于治疗精神分裂症的联苯芦诺剂量 | |
| JP2018035086A (ja) | 低活動膀胱の予防及び／又は治療薬 | |
| HK1133190A (en) | Bifeprunox doses for treating schizophrenia | |
| WO2009054929A1 (en) | Cannabinoid-1 receptor modulators useful for the treatment of alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140827 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250307 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250307 |